<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994029</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2278</org_study_id>
    <nct_id>NCT03994029</nct_id>
  </id_info>
  <brief_title>Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance</brief_title>
  <official_title>Effect of Polyphenol Supplementation on Hepatic Steatosis, Non-invasive Vascular Elastography and Intima Media Thickness in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study the effect of polyphenol supplementation on hepatic steatosis
      as measured by hepatic ultrasound, hepatic elastography and magnetic resonance hepatic
      spectroscopy in obese adolescents known for hepatic steatosis as diagnosed by liver biopsy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity leads to hepatic steatosis. Early changes in vascular compliance due to obesity have
      been shown to be reversible. Many studies have shown a positive effect of polyphenols
      (natural product in apples and grapes) on the liver fat burden. Three visits will be
      planified.

      Visit 1: Demographic data and liver and vascular imaging. Blood and stool tests.

      Randomization to polyphenol versus placebo. Visit 2 at 60 days. Demographic data and liver
      and vascular imaging. Blood tests. Stop the intervention.

      Visit 3 at 120 days. Demographic data and liver and vascular imaging. Blood and stool tests.

      This study will determine the feasibility of a randomized controlled trial evaluating the
      effect of polyphenols on hepatic steatosis and the vascular subclinical radiologic changes
      related to obesity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic steatosis MR</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>MR spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hepatic steatosis US Shear wave elastography</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>US elastography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hepatic steatosis B-mode US</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Conventional US</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in intima media thickness</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Measurement of carotid artery intima media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vascular compliance</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Non invasive vascular elastography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity, Childhood</condition>
  <condition>Hepatic Steatosis</condition>
  <condition>Intimal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Polyphenol supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg per day of powder polyphenol for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tab PO QD per day of placebo for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness</intervention_name>
    <description>Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Polyphenol supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents 13-&lt; 18

          -  Residing in the Montreal area

          -  BMI &gt; 30Kg/mÂ² (&gt; 95th percentile for age and sex)

          -  Hepatic MRI spectroscopy showing ratio &gt; 5.5% lipid/water

          -  Not being pregnant (if sexually active, using an effective contraceptive method)

        Exclusion Criteria:

          -  chronic disease, including diabetes, hypercholesterolemia, hypertension, hepatitis
             (viral and autoimmune), Wilson's disease and Alpha 1 antitrypsin.

          -  Taking medications or supplements

          -  Having a weight loss in the last 6 months prior to recruitment

          -  Alcohol consumption &gt; 2 drinks per day or consume more than 1 day per week

          -  Known peanut allergies

          -  Contraindications for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramy El Jalbout, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Principal investigator</last_name>
    <phone>5143454931</phone>
    <email>ramy.el-jalbout.hsj@ssss.gouv.qc.ca</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Ramy El Jalbout</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

